Immunogenicity and efficacy of XBB.1.5 rS vaccine against EG.5.1 variant of SARS-CoV-2 in Syrian hamsters
Adrianus C. M. Boon, Meredith E. Davis-Gardner(Emory University), Tamarand L. Darling(Washington University in St. Louis), Ali H. Ellebedy(Washington University in St. Louis), Mehul S. Suthar(Emory University), Kuljeet Seehra(Washington University in St. Louis), Traci L. Bricker(Washington University in St. Louis), Nadia Soudani(Washington University in St. Louis), Gale Smith(Novavax (United States)), Nita Patel(Novavax (United States)), Mimi Guebre‐Xabier(Emory University)
Cited by 3
Related Papers
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
|Cell Host & Microbe|2021|851